ReviewFrontiers in oncology2025
CD44 targeted functionalized nanocarriers for non-small cell lung cancer.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is a significant worldwide health concern, requiring novel treatment strategies. This review presents the potential of CD44-targeted functionalized nanocarriers as effective tools for treating NSCLC. CD44, a glycoprotein found on surface of cells, is known for being excessively expressed in NSCLC, making it a promising target for targeted drug delivery. The review begins by examining CD44 as a crucial biomarker in NSCLC. The text provides an overview of molecular features of NSCLC. These fundamental concepts provide the framework for comprehending the reasoning behind the focused strategy of medication delivery using nanocarriers. The review discusses the importance of key factors, such as the dimensions, morphology, and electrostatic properties of nanocarriers, in relation to their influence on interactions with CD44 receptors. The review provides an assessment of preclinical and clinical research that has examined the use of CD44-targeted nanocarriers in the treatment of NSCLC. The review further provides an analysis of safety concerns and possible difficulties, like immunogenicity and off-target effects, in relation to CD44-targeted nanocarriers. This review provides helpful guidance to researchers and clinicians who are interested in using CD44-targeted nanocarriers for more precise and efficient therapies of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.